In Florida overlooking the Intercoastal Waterway..
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I wonder if this is a pump or not.. You sure seem overly confident in your numbers.. Could you verify..??? It would help all because at present it looks like the $0.003's are close.. Only one bid of 1,000,000 at $0.004 to slow the trend.. hank
Good for you.. If you think it's a good opp. to load up at this level you should and I'm sure the converters will manufacture you any amount of shares you want.. ACGX is a fine little company,, Too bad ACGX had to issue so far over 580,000,000 shares to pay off a debt that caused it's EPS to go from $0.12 per share to Nil.. What is really sad is that they had the money to pay them off.. But if you control by the preferred what difference does it make to you/them..?? When ACGX had $0.12 in earnings it only sold for $0.02 on a good day.. Someone smarter than me was a seller then and I realized that my ownership went down 25% in reality each time they issued a new report on how many shares were out.. The converters were busy then as they are now.. ..
But as I have been explained to this is a sub-penny stock and it's even unusual for them to have earnings.. Could be there still is another roar out of the pig still but I'll stay on the sidelines and leave the buying up to you.. Good luck.. hank GLTA hank
I'm sure eveyone else can divide today's shares by 8.5 Miliion.. Hopefully you can also.. hank
ACGX.. $0.0047.. Hope this helps with your question.. Here is a PR from the company.. It actually was in 22 months since the shares went from 8.5 million to today's total,,
Turning into..?? Didn't you read the last PR by the company that said it had 1.4 billion in shorts in the stock and the one before that that the company PR'ed that the stock was worth $0.05 per share.. If all this is true why don't it go up..?? wary longs will always ask that the ask be slapped.. It's their turn if they believe..
Ask the company to release the latest share count..
It has only risen 73 Times in the past 23 Months.. When you go from 8.5 million shares to almost 600 Million the buyers get tired and wore down because each spike on buying creates selling and an increase in the shares outstanding.. This is fact.. hank
If it doesn't trade any where but on the bid how will it go up..?? 25% of today's volume just trades at $0.0052..
Bid just raised to $0.0049..(10,000 Shares=$49.00..) Bid support getting stronger.. Follow the WAVE..
That's very possible,, especially if you don't have an axe in the game.. hank
ACGX.. $.0048.. One share just traded.. ??? It (L2) really is meaningless if the stock doesn't trade.. At present the Ask is loaded and the Bid's are dwindling.. Looks like those that use the bid to buy are the smart ones.. Less than 360,000 shares bid for before $0.036.. $0.0034 has a bid of 1 Mil.. hank
Where did every one go.. It appears that the continued ACGX selling has just wore everyone out.. take a page from history on this.. Every spike is followed by long periods of boredom and continued selling..
Take a rest and come back in a month with a new base to start from.. The conference Info seems to go on deft ears just like the short interest..
===================================================
Jeff Macke of Breakout published an article recently, titled, “Why ‘cheap’ stocks are for suckers.” Macke’s article brings up a couple of good points:
•“Dollar value per share doesn’t tell the whole story;” and
•Reverse splits can “mask… ineptitude.”
Macke notes that market capitalization–the cost per share multiplied by the number of shares–is more telling than share price. This is absolutely true. A $3/share company with 100 million shares outstanding has a market cap of $300 million. On the other hand, a $30/share company with 10 million shares outstanding has the same market cap. The $3/share company is cheaper per share, but is actually valued the same. That’s why considering share structure is absolutely crucial!
All small stocks are not great investments, but because you invest in small stocks does not make you a “sucker.” Our subscribers certainly would not think so. While the general investing public continues to view our coveted “cheap” stocks as the outcasts of the market, we’ll continue to help our subscribers find winners in the minipriced arena.
That could be a holder from the last reverse when they received 1 share for 2000 just cleaning out a position to be able to take a tax loss..
ACGX. $0.0047.. BUY SMART,, USE THE BID TO BUY,, Have patience and let the bid wackers come to you.. THEY WILL FIND YOU,, DON'T WORRY..
Wow it seems according to this report that almost all shares are being sold short.. Could it be shares are shorted against the Box and awaiting delivery..?? Remember 1.4 billion shares short exceeds the total cap including the conversion from the president's shares.. That in effect a corner times 2..
Suspicious bad info but it is on the Company's web site as a PR.. Good info to have if you are selling into it.. Since that date of the PR the short sales have increased as a percentage of total sales..
That is of course if one believes the data bought and paid for or should you believe the data from OTC filing releases that shows no short sales..??
it's all important that those that believe also hope they are right,, but the shares still seem to be avil. on the ask and if not taken the bids continued to get wacked making those that believe feel more squirmish with every downtic.. Since a Debt holder one is always able to buy 20% below the market makes a good enough reason to continuie sell IMO..
Remember Because No one/debt converter may hold more than 9.9% of the outstanding,, so in order to get paid one must sell,, sell,, sell and sell some more..
As usual when the converters sell we get no share updates..hank
TEXC.. $0.30.. This is big and I think we will have a $6.00 stock after these deals are done..
Has anyone ever heard of a brokerage firm that will allow you to short a sub-penny stock.. According to stock records at present there are no shorts in the stock,, This is the same PR Crap that preceded the famous Money Manager meeting before XMAS. that was attended by only the presenters..
BTW ACGX also sponsored the printing for that one.. What ever happened to the 10% of On-line sales that were going to charity.. Was there any donations made or was that also fluff.. Next Share Up-date should be interesting as there has been little volume.. must be all the shorts selling but thru who.. You need margin requirements at the least to short.. Wonder what the Margin maintenance requirements would be..?? hank
It was invented here by the previous companies that ACGX was at one time before it's latest merger.. Dilue and reverse.. Control with the preferred..
They don't dispute it as rubbish and infact post it on their website.. Just like the lame report that said ACGX was worth $0.05..
Do the math.. 1.6 Billion fully diluted shares times $0.05.. There are many companies on the NYSE not worth that with earnings more than ACGX has sales.. Get Real..
Who do you think is selling lately..?? Any news on the new sharecounts.. You know while they are diluting they never put out updated info..
When you are of the mentality of ACGX Management anything that may be used to sell stock is a worthwhile in a PR.. I don't know who compiles these figures but I'm sure they get paid to serve the pumpers at any company they report on..
For a company to use this bad Info as a press release proves that there really is no way to hide the share increase by 73 times in 22 months since they have reported it,, but instead trying to blame the stocks action on the naked shorts to those that don't read filings of a company..
The rehashing of parts of ACGX press releases over and over again by some lend credence to the fact that ACGX has no news to publish that will/may/could continue to keep alive the hopes of the longs..
If the company realy believed there were that many shorts a reverse of any size would cause a stampede to buy and the stock would be trading at a dollar.. A 1 for 1.01 would do the trick.. But the real trick is making the uninformed believe that the short interest numbers are infact true.. HAS any one ever tried to short a sub penny stock.. Where and at what broker can you go.. hank..
It's not that hard to figure.. First the president can convert for 800 Million,, the company has over 600 Million outstanding and there is over 1 Million in debt left to be converted.. As to restriction,, the only one that there is that no person or group debtor can own more than 9.9% of the company at any time so that forces conversion if the debt holders want their money.. All conversions are at a discount of at least 20% to the market.. Hope this helps..
In addition the President seems to be able at will to increase his conversion rate on the preferred .. The last time he did it he increased his shares by 400 million shares w/o any compensation to other shareholders..
Just what does this type of posting have to do with the value and trading in the stock of ACGX.. I think Verifiable Information as to the Balance Sheet.. Discussing capitol structure of ACGX make more sense when making investment decisions..
As to them many locations of ACGX it appears that some are no more than Telephone numbers..
ACGX is a nice little business ,, But,, smaller than the Ave. Hallmark store at the Ave. Mall and has over 600 Million shares outstanding ... If all debt and preferred conversions were made there would be over 2 billion shares outstanding.. Those are the facts and unless someone finds something different please let us all know.. hank
Buy smart,, Put up a bid and let the sellers come to you.. They will.. hank
I thought about it but due to several of PM's asking me to stay to show the otherside of the coin I decided to stay.. At present positive posts out number negative posts 16 to one and posts that contain factual information that can be verified are outnumbered 45 to one.. Posts which contain projections as to a higher close are now 28% of all posts.. The posts containing shorts are down 94%.. hank
ACGX.. $0.0048.. Promises,, Promises and intentions made by all that say they are buying would have ACGX selling at a Dollar.. hank
GATA $0.25.. is getting interesting.. I think it finally has some traction.. Always thought it was cheap on the earnings but the INDIA factor always seemed to make it have ready and willing sellers.. I'm long a bunch lower and nave taken more of an investor stance on GATA than using it as a trading Stock... hank
It appears that their last six trades on ACGX would of created a loss each time.. Could be that's why there is no buying this morning.. hank
When did they say to start buying..??
Not for long,, I sold when the shares exploded to 12.2 Million or by 50% above where they were when I bought in.. BTW then as now the story on the conversion was the same except that they now have exploded the share count by 62 times..
Whats next..?? 2.4 billion looks in the bag as there is much more left of the 1.5 million debt to be converted plus the Preferred exchange of 800 Million.. ( that is of course if the president doesn't decide as he has done in the past to increase his share exchange values.. W/O any compensation or benefit to current shareholders)
They also said that while they had the money to pay off all debt in hand that it was more prudent to save the cash and dilute shareholders by 99.25... At the same time increasing their conversion rights by 800 Million shares w/o any compensation to same shareholders..
That in itself make one wonder why the reason ACGX is public.. Thier shareholders seem to have no say in any management decisions and at the same time have watched their interest's diluted by 99.2% during the past 22 Months.. Doesn't seem like a good stock to own,, does it ..??
Sure it could go up thru what some have called controlled conversions but it appears these conversions continue to choke the life out of any meaningful upwards movement.. hank
The only thing that would stop the Converters is if ACGX was halted.. ACGX has always had converters and the latest round prob. exausted their 60 Million shares converted just before the last move to a penny..
At present I doubt if many conversions are taking place because the price is too high but still at a 20% discount to the market there is enough room for profit..
If the conversions were @ 0.05 price level their conversion price would be $0.04 and selling at today's level would give them a 30% profit Vrs. conversion prices.. If conversion was made at that price they usually will wait until as before that this lot has been sold to report..
But it is also true that IF they have stopped conversions ,, a simple reporting of current shares outstanding would confirm this if they wanted to report..
As to my logic being faulty,, that is up to interpretation and I believe I have history on my side as they have increased the shares outstanding by 72 times in the past 22 Months.. 72 Times is quite a feat for a company that has always had the ability to pay off it's debt.. But since the shares are controlled thru the preferred and as long as they keep 1 share of the preferred they control.. Recent increases in the conversion rate of the preferred by 400 Million shares by the president W/O any compensation to other shareholders leaves little open for interpretation in my view as to what the intention are for these shares.. If you disagree that your right but the history of the last 2 years conversion and their reason to dilute shareholders by 99.2% should be taken into consideration when any purchases of ACGX are made.. .. hank
KLYG.. $0.162.. I hope all copy cat sellers have their day and move KLYG back down to where the day started as I will add on a Pear style Ave. on the way down.. .. This stock is not for flippers and any shares bought,, in my opinion from this level will be 10-bagger if not higher inventory.. I no longer look at KLYG as a lottery ticket but a Micro-Cap Growth story with a possibility of a buyout potential in the making..
As we get closer to the 100 year date of Salt Flat's racing I will be less involved with day to day trading and market making .... KLYG,, ERLIF,, HLTZF,, JGPK,, MBXBF,, RNWEY,, TEXC,, are examples of 10-bagger material I've been looking at lately and Positions in GATA,, GPIW,, MNVWF,, OPBK,, PHMZF,, POLXF,, SCIA,, SPND,, should have nice moves before yearend.. .. hank
KLYG.. $0.188 Past RR releases not easily avil. for futher DD and Research are shown below..
Hopefully KLYG backoff's from today's spike will happen as I now believe that KLYG is no longer a lottery ticket but has a good possibility of becoming a true Micro-cap growth stock.. I will add on any weakness.. Normally close lipped management has come out with New members to the board that will give it exposure thruout the industry which it serves.. Over a year ago a published letter to a respected Nuerosurgeon Journal was written by a respected Nuerosurgeon that seemed to aid in the validity of its procedures and methods of expertise in cranial bone repair.. The new additions to the board will again further their penetration into this new and exciting field.. This Journal Article is contained in a PR below..
I think that with just a few more Qtr's of continued performance a buyout could very well happen and at the least a ten-bagger from this level.. Continued growth and earnings at this rate could very well place KLYG into the high multiple values given medical device companies..
Personally I think KLYG could be a life changing stock for any that continue to own it.. hank
=============================================================
Kelyniam Announces Record Net Income and Additions to the Board of Directors
GlobeNewswire - Jun 03 09:48 EDT
Alert hits:OTC All /kl
Company Symbols: OTC-PINK:KLYG
Canton, CT, June 3, 2014 (GLOBE NEWSWIRE) -- Kelyniam Global Inc, (OTC: KLYG), a prominent manufacturer of custom cranial implants, today reported that the company generated net income of $71,205 in the first quarter of 2014.
Compared with first quarter 2013, net sales increased 23% from $437,415 to $540,286, as a result of increased market penetration, gross profit moved up from $229,027 to $269,788, and net income swung from a loss of $17,272 to a profit of $71,205. Financials will be provided at www.kelyniam.com. "This is the strongest first quarter in the company's history", stated Tennyson Anthony, President and CEO. "Our progress is encouraging and it suggests there is a lot more room for the company to grow. Furthermore, we are working to increase our gross margins throughout 2014."
In addition, the company is excited to announce that the board has appointed Dr. Mark Smith, a prominent Nuerosurgeon, and Dr. Naveh Levy, a practicing Diagnostic Radiologist, to the board of directors.
Mark V Smith, M.D. is a neurosurgeon with over 20 years of clinical experience. He has also worked as a biomedical engineer. He graduated magna cum laude with a bachelor's degree in Electrical Engineering from the University of Maryland in 1980. After working two years as a biomedical engineer, he was admitted to medical school where he earned a doctorate of medicine at the University of Maryland in 1986. He completed his neurosurgery training at SUNY Upstate University Hospital in Syracuse, New York in 1993. He is also fellowship trained in pituitary surgery and epilepsy surgery. Dr. Smith was as an assistant professor of neurological surgery at SUNY Health Sciences Center in Syracuse, New York from 1994 to 1999 specializing in epilepsy and skull base surgery. In 1999 he started a private practice neurosurgery group in Utica, New York. Dr. Smith has received numerous awards and grants and is published in the fields of neuroanatomy, neurophysiology and neurosurgery.
Naveh Levy, M.D. completed his residency at the Cleveland Clinic in 2008 and an MRI Fellowship in 2009 at Michigan State University. He holds a medical degree from George Washington University School of Medicine in Washington, D.C.
"Kelyniam is in the business of taking raw data, a patient's CT scan, and creating a superior product with intricate details for the surgeon to implant in the patient. These new board members bring the technological acumen to complement both aspects of the business," stated Mr Anthony. "We are excited to have them join us."
=============================================================
Kelyniam Global Inc. Revenues Grow 54% from Prior Year
GlobeNewswire - Apr 07 08:30 EDT
Alert hits:/kl
Company Symbols: OTC-PINK:KLYG
Canton, CT, April 7, 2014 (GLOBE NEWSWIRE) -- Kelyniam Global Inc.(OTC: KLYG), a manufacturer of custom cranial implants, announces preliminary revenue of $1,857,516 for 2013. This represents an increase of 54% vs. sales of $1,206,227 in 2012. The Kelyniam product fit and quick turnaround has captured the attention of surgeons throughout the United States. The revenue increase reflects the continued rollout in many additional hospitals. The company will provide financials on their website, kelyniam.com, when they become available in final form from the Accounting Firm.
President and CEO Tennyson S. Anthony stated: "Although we are showing consistent growth and have become a profitable company in a relatively short time, rest assured we are focused on building a company that has the ability to grow at a much greater rate in the near future. My team and I have been working tirelessly to create a company that has the technology, economic fortitude, and operational efficiency to be the market leader in customized implants. We are just starting to see the fruits of our efforts."
=============================================================
Kelyniam Global Inc. Unveils New Product
Canton, CT, April 2, 2014 (GLOBE NEWSWIRE) -- Kelyniam Global Inc. has introduced a new product to the marketplace, the "IFS" (Integrated Fixation System) product. The product is patent pending and provides faster implantation, reduced hardware, cost savings and elimination of mundane tasks during the surgical procedure.
The design team at Kelyniam created this product with the surgeons needs in mind together with the realization of economic sensitivities by the hospitals. They carefully collected feedback and input from a multitude of surgeons and designed the product to make their surgeries more efficient.
Kelyniam will be unveiling the new product at the 82nd Annual AANS (American Association of Neurological Surgeons) meeting April 5-9, 2014 in San Francisco.
The company also expects to report financials for 2013 in the coming weeks.
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
===================================================================
KLYG.. $0.1388.. I think it's a table pounder but I need to see one more Qtr.. It's been my lottery ticket for 2 years.. Kelyniam Global Inc. turns profitable during the second quarter of 2013
Canton, CT, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Kelyniam Global Inc. (OTC: KLYG) ("the company") is pleased to announce that it has posted its first ever quarterly profit, for the quarter ending June 30, 2013. Net income for the second quarter was $6,608. Sales in the second quarter were $593,355, up 35% from $438,415 in the first quarter 2013. Year to date sales were $1,031,770, up 253% from the same period in 2012.
The company continues to deploy capital towards marketing and organic growth, and to build market share as its customized PEEK implants are sold in more hospitals than ever. It has recently negotiated better terms for the DECD note secured last year, with the term of the note changing from 5 years to 10 without any increase in the interest rate.
Kelyniam will be an active participant in the Connecticut Economic Trade Mission to Australia later this week, traveling to both Sydney and Canberra, Australia. President & CEO Tennyson Anthony exclaimed, "While we are pleased with our second quarter performance, it is our goal to be used in all 50 states and internationally as well." He continued, "In fact, our growth is not only focused on geography, but on building on our existing products. The company will be announcing a new product in the months to come, one that we feel will turn heads."
The company will be posting the financial tables on the website www.kelyniam.com
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
Please visit our website at www.kelyniam.com for more information.
==========================================
KLYG.. $0.1078.. My LOTTERY TICKET,, It moves on air.. Now meeting projections made last year...
Kelyniam Global Inc. Announces Continued Revenue Growth & Approval to Sell Overseas
Canton, CT, May 30, 2013 (GLOBE NEWSWIRE) -- Kelyniam Global Inc. (OTC: KLYG), a growing company that designs, manufactures, and sells custom cranial/craniofacial implants, announced today its financial results for the year ending December 31, 2012 and also for the first quarter ended March 31, 2013.
Revenues for the year ending December 31, 2012 totaled $1.2 million. 2012 was the first full calendar year the company had manufactured and sold custom cranial implants in the United States. Revenues for the fourth quarter of 2012 were $414,982 up from $382,177 in the third quarter 2012.
First quarter 2013 revenues were a record $437,415, an increase of 207% from $210,635 in the first quarter of 2012. The increase in sales was attributed to continued marketing and promotional efforts across the United States. The first quarter 2013 marks the first time the company has broken even on an accrual basis.
The 2013 year brings the headwind of the medical device tax to the industry. Beginning Jan 2013 and unless Obamacare is repealed; Kelyniam will be liable for a 2.3% tax on all medical device sales.
A further note: Kelyniam is pleased to announce it has recently been approved to sell its custom cranial/craniofacial implants in Kuwait. It anticipates sales to begin in the coming months.
Related unaudited financial tables will be posted on the company's website www.kelyniam.com.
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
Please visit our website at www.kelyniam.com for more information.
Source: Kelyniam Global Inc.
2013 GlobeNewswire, Inc.
---------------------------------------------------
Kelyniam Custom Cranial Implants Receive Endorsement From Skull Based Neurosurgeon Dr. Ammirati of The Ohio State University Wexner Medical Center
Canton, CT, Jan. 29, 2013 (GLOBE NEWSWIRE) -- (OTC: KLYG) Kelyniam Custom Cranial Implants, designed to fill the boney void in a patient's skull, have been endorsed by Mario Ammirati, MD, Director of Skull Based Surgery, Stereotactic Radiosurgery and the Dardinger Microneurosurgical Skull Based Laboratory, Wexner Medical Center, at the Ohio State University. This is the first product Dr. Ammirati has ever endorsed.
Dr. Ammirati stated: "As a neurosurgeon specializing in skull based surgery and brain tumors, I am encouraged with the advancements Kelyniam has made in patient customized cranial implants. I am extremely happy with the precision fit and the fast service I receive with every case. Complex cranial defects resulting from trauma or oncologic resection present reconstructive challenges. No matter how complex the defect, Kelyniam's implant design team is very responsive to my needs. They understand the surgical plans and are quick to respond to my design requirements. The end result is a product that fits very well and is quick to implant, thereby reducing O.R. time and providing the patient with excellent aesthetic results."
----------------------------------------
Kelyniam Global Inc. Announces Record Revenues
GlobeNewswire - Jan 15 08:15 EDT
Alert hits:/kl
Company Symbols: OTC-PINK:KLYG
Canton, CT, Jan. 15, 2013 (GLOBE NEWSWIRE) --
Third Quarter
Kelyniam is pleased to announce record quarterly revenues of $382,177 for the third quarter ending September 30th 2012. This represents almost double the product revenue produced in the second quarter 2012. The company continues to penetrate the custom cranial implant marketplace and has sold implants to medical institutions in more than 20 different states. Furthermore, the company has sold the first maxiofacial implants in the fourth quarter as a result of the recent FDA 510k approval in late third quarter.
Fourth Quarter
The debut of Kelyniam maxiofacial implants in the fourth quarter was met with orders. These orders combined with existing custom cranial implant orders propelled revenues to approximately $400,000 for the fourth quarter, exceeding internal expectations of a slow quarter due to multiple holidays and fewer surgeries. Final fourth quarter numbers will be released once a full accounting is complete.
"The final two quarters of the year demonstrate that both the custom cranial and maxiofacial implant markets have capacity for a product of superior design. Management has worked hard to right the ship in 2012 and looks to build on the momentum in 2013" stated President and CEO Tennyson Anthony. "Kelyniam not only has created a product that fills the patient's cranial void, but is filling the void in the marketplace for a timely-delivered well-fitting product."
Upcoming Conference
Kelyniam will be exhibiting once again at the North American Skull Base Society (NASBS) February 15th - 17th, in Miami, FL.
Financial tables can be found on the company's website www.kelyniam.com
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
Please visit our website at www.kelyniam.com for more information.
KLYG.. $0.188 Past RR releases not easily avil. for futher DD and Research are shown below..
Hopefully KLYG backoff's from today's spike will happen as I now believe that KLYG is no longer a lottery ticket but has a good possibility of becoming a true Micro-cap growth stock.. I will add on any weakness.. Normally close lipped management has come out with New members to the board that will give it exposure thruout the industry which it serves.. Over a year ago a published letter to a respected Nuerosurgeon Journal was written by a respected Nuerosurgeon that seemed to aid in the validity of its procedures and methods of expertise in cranial bone repair.. The new additions to the board will again further their penetration into this new and exciting field.. This Journal Article is contained in a PR below..
I think that with just a few more Qtr's of continued performance a buyout could very well happen and at the least a ten-bagger from this level.. Continued growth and earnings at this rate could very well place KLYG into the high multiple values given medical device companies..
Personally I think KLYG could be a life changing stock for any that continue to own it.. hank
=============================================================
Kelyniam Announces Record Net Income and Additions to the Board of Directors
GlobeNewswire - Jun 03 09:48 EDT
Alert hits:OTC All /kl
Company Symbols: OTC-PINK:KLYG
Canton, CT, June 3, 2014 (GLOBE NEWSWIRE) -- Kelyniam Global Inc, (OTC: KLYG), a prominent manufacturer of custom cranial implants, today reported that the company generated net income of $71,205 in the first quarter of 2014.
Compared with first quarter 2013, net sales increased 23% from $437,415 to $540,286, as a result of increased market penetration, gross profit moved up from $229,027 to $269,788, and net income swung from a loss of $17,272 to a profit of $71,205. Financials will be provided at www.kelyniam.com. "This is the strongest first quarter in the company's history", stated Tennyson Anthony, President and CEO. "Our progress is encouraging and it suggests there is a lot more room for the company to grow. Furthermore, we are working to increase our gross margins throughout 2014."
In addition, the company is excited to announce that the board has appointed Dr. Mark Smith, a prominent Nuerosurgeon, and Dr. Naveh Levy, a practicing Diagnostic Radiologist, to the board of directors.
Mark V Smith, M.D. is a neurosurgeon with over 20 years of clinical experience. He has also worked as a biomedical engineer. He graduated magna cum laude with a bachelor's degree in Electrical Engineering from the University of Maryland in 1980. After working two years as a biomedical engineer, he was admitted to medical school where he earned a doctorate of medicine at the University of Maryland in 1986. He completed his neurosurgery training at SUNY Upstate University Hospital in Syracuse, New York in 1993. He is also fellowship trained in pituitary surgery and epilepsy surgery. Dr. Smith was as an assistant professor of neurological surgery at SUNY Health Sciences Center in Syracuse, New York from 1994 to 1999 specializing in epilepsy and skull base surgery. In 1999 he started a private practice neurosurgery group in Utica, New York. Dr. Smith has received numerous awards and grants and is published in the fields of neuroanatomy, neurophysiology and neurosurgery.
Naveh Levy, M.D. completed his residency at the Cleveland Clinic in 2008 and an MRI Fellowship in 2009 at Michigan State University. He holds a medical degree from George Washington University School of Medicine in Washington, D.C.
"Kelyniam is in the business of taking raw data, a patient's CT scan, and creating a superior product with intricate details for the surgeon to implant in the patient. These new board members bring the technological acumen to complement both aspects of the business," stated Mr Anthony. "We are excited to have them join us."
=============================================================
Kelyniam Global Inc. Revenues Grow 54% from Prior Year
GlobeNewswire - Apr 07 08:30 EDT
Alert hits:/kl
Company Symbols: OTC-PINK:KLYG
Canton, CT, April 7, 2014 (GLOBE NEWSWIRE) -- Kelyniam Global Inc.(OTC: KLYG), a manufacturer of custom cranial implants, announces preliminary revenue of $1,857,516 for 2013. This represents an increase of 54% vs. sales of $1,206,227 in 2012. The Kelyniam product fit and quick turnaround has captured the attention of surgeons throughout the United States. The revenue increase reflects the continued rollout in many additional hospitals. The company will provide financials on their website, kelyniam.com, when they become available in final form from the Accounting Firm.
President and CEO Tennyson S. Anthony stated: "Although we are showing consistent growth and have become a profitable company in a relatively short time, rest assured we are focused on building a company that has the ability to grow at a much greater rate in the near future. My team and I have been working tirelessly to create a company that has the technology, economic fortitude, and operational efficiency to be the market leader in customized implants. We are just starting to see the fruits of our efforts."
=============================================================
Kelyniam Global Inc. Unveils New Product
Canton, CT, April 2, 2014 (GLOBE NEWSWIRE) -- Kelyniam Global Inc. has introduced a new product to the marketplace, the "IFS" (Integrated Fixation System) product. The product is patent pending and provides faster implantation, reduced hardware, cost savings and elimination of mundane tasks during the surgical procedure.
The design team at Kelyniam created this product with the surgeons needs in mind together with the realization of economic sensitivities by the hospitals. They carefully collected feedback and input from a multitude of surgeons and designed the product to make their surgeries more efficient.
Kelyniam will be unveiling the new product at the 82nd Annual AANS (American Association of Neurological Surgeons) meeting April 5-9, 2014 in San Francisco.
The company also expects to report financials for 2013 in the coming weeks.
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
===================================================================
KLYG.. $0.1388.. I think it's a table pounder but I need to see one more Qtr.. It's been my lottery ticket for 2 years.. Kelyniam Global Inc. turns profitable during the second quarter of 2013
Canton, CT, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Kelyniam Global Inc. (OTC: KLYG) ("the company") is pleased to announce that it has posted its first ever quarterly profit, for the quarter ending June 30, 2013. Net income for the second quarter was $6,608. Sales in the second quarter were $593,355, up 35% from $438,415 in the first quarter 2013. Year to date sales were $1,031,770, up 253% from the same period in 2012.
The company continues to deploy capital towards marketing and organic growth, and to build market share as its customized PEEK implants are sold in more hospitals than ever. It has recently negotiated better terms for the DECD note secured last year, with the term of the note changing from 5 years to 10 without any increase in the interest rate.
Kelyniam will be an active participant in the Connecticut Economic Trade Mission to Australia later this week, traveling to both Sydney and Canberra, Australia. President & CEO Tennyson Anthony exclaimed, "While we are pleased with our second quarter performance, it is our goal to be used in all 50 states and internationally as well." He continued, "In fact, our growth is not only focused on geography, but on building on our existing products. The company will be announcing a new product in the months to come, one that we feel will turn heads."
The company will be posting the financial tables on the website www.kelyniam.com
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
Please visit our website at www.kelyniam.com for more information.
==========================================
KLYG.. $0.1078.. My LOTTERY TICKET,, It moves on air.. Now meeting projections made last year...
Kelyniam Global Inc. Announces Continued Revenue Growth & Approval to Sell Overseas
Canton, CT, May 30, 2013 (GLOBE NEWSWIRE) -- Kelyniam Global Inc. (OTC: KLYG), a growing company that designs, manufactures, and sells custom cranial/craniofacial implants, announced today its financial results for the year ending December 31, 2012 and also for the first quarter ended March 31, 2013.
Revenues for the year ending December 31, 2012 totaled $1.2 million. 2012 was the first full calendar year the company had manufactured and sold custom cranial implants in the United States. Revenues for the fourth quarter of 2012 were $414,982 up from $382,177 in the third quarter 2012.
First quarter 2013 revenues were a record $437,415, an increase of 207% from $210,635 in the first quarter of 2012. The increase in sales was attributed to continued marketing and promotional efforts across the United States. The first quarter 2013 marks the first time the company has broken even on an accrual basis.
The 2013 year brings the headwind of the medical device tax to the industry. Beginning Jan 2013 and unless Obamacare is repealed; Kelyniam will be liable for a 2.3% tax on all medical device sales.
A further note: Kelyniam is pleased to announce it has recently been approved to sell its custom cranial/craniofacial implants in Kuwait. It anticipates sales to begin in the coming months.
Related unaudited financial tables will be posted on the company's website www.kelyniam.com.
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
Please visit our website at www.kelyniam.com for more information.
Source: Kelyniam Global Inc.
2013 GlobeNewswire, Inc.
---------------------------------------------------
Kelyniam Custom Cranial Implants Receive Endorsement From Skull Based Neurosurgeon Dr. Ammirati of The Ohio State University Wexner Medical Center
Canton, CT, Jan. 29, 2013 (GLOBE NEWSWIRE) -- (OTC: KLYG) Kelyniam Custom Cranial Implants, designed to fill the boney void in a patient's skull, have been endorsed by Mario Ammirati, MD, Director of Skull Based Surgery, Stereotactic Radiosurgery and the Dardinger Microneurosurgical Skull Based Laboratory, Wexner Medical Center, at the Ohio State University. This is the first product Dr. Ammirati has ever endorsed.
Dr. Ammirati stated: "As a neurosurgeon specializing in skull based surgery and brain tumors, I am encouraged with the advancements Kelyniam has made in patient customized cranial implants. I am extremely happy with the precision fit and the fast service I receive with every case. Complex cranial defects resulting from trauma or oncologic resection present reconstructive challenges. No matter how complex the defect, Kelyniam's implant design team is very responsive to my needs. They understand the surgical plans and are quick to respond to my design requirements. The end result is a product that fits very well and is quick to implant, thereby reducing O.R. time and providing the patient with excellent aesthetic results."
----------------------------------------
Kelyniam Global Inc. Announces Record Revenues
GlobeNewswire - Jan 15 08:15 EDT
Alert hits:/kl
Company Symbols: OTC-PINK:KLYG
Canton, CT, Jan. 15, 2013 (GLOBE NEWSWIRE) --
Third Quarter
Kelyniam is pleased to announce record quarterly revenues of $382,177 for the third quarter ending September 30th 2012. This represents almost double the product revenue produced in the second quarter 2012. The company continues to penetrate the custom cranial implant marketplace and has sold implants to medical institutions in more than 20 different states. Furthermore, the company has sold the first maxiofacial implants in the fourth quarter as a result of the recent FDA 510k approval in late third quarter.
Fourth Quarter
The debut of Kelyniam maxiofacial implants in the fourth quarter was met with orders. These orders combined with existing custom cranial implant orders propelled revenues to approximately $400,000 for the fourth quarter, exceeding internal expectations of a slow quarter due to multiple holidays and fewer surgeries. Final fourth quarter numbers will be released once a full accounting is complete.
"The final two quarters of the year demonstrate that both the custom cranial and maxiofacial implant markets have capacity for a product of superior design. Management has worked hard to right the ship in 2012 and looks to build on the momentum in 2013" stated President and CEO Tennyson Anthony. "Kelyniam not only has created a product that fills the patient's cranial void, but is filling the void in the marketplace for a timely-delivered well-fitting product."
Upcoming Conference
Kelyniam will be exhibiting once again at the North American Skull Base Society (NASBS) February 15th - 17th, in Miami, FL.
Financial tables can be found on the company's website www.kelyniam.com
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
Please visit our website at www.kelyniam.com for more information.
KLYG.. $0.188 Past RR releases not easily avil. for futher DD and Research are shown below..
Hopefully KLYG backoff's from today's spike will happen as I now believe that KLYG is no longer a lottery ticket but has a good possibility of becoming a true Micro-cap growth stock.. I will add on any weakness.. Normally close lipped management has come out with New members to the board that will give it exposure thruout the industry which it serves.. Over a year ago a published letter to a respected Nuerosurgeon Journal was written by a respected Nuerosurgeon that seemed to aid in the validity of its procedures and methods of expertise in cranial bone repair.. The new additions to the board will again further their penetration into this new and exciting field.. This Journal Article is contained in a PR below..
I think that with just a few more Qtr's of continued performance a buyout could very well happen and at the least a ten-bagger from this level.. Continued growth and earnings at this rate could very well place KLYG into the high multiple values given medical device companies..
Personally I think KLYG could be a life changing stock for any that continue to own it.. hank
=============================================================
Kelyniam Announces Record Net Income and Additions to the Board of Directors
GlobeNewswire - Jun 03 09:48 EDT
Alert hits:OTC All /kl
Company Symbols: OTC-PINK:KLYG
Canton, CT, June 3, 2014 (GLOBE NEWSWIRE) -- Kelyniam Global Inc, (OTC: KLYG), a prominent manufacturer of custom cranial implants, today reported that the company generated net income of $71,205 in the first quarter of 2014.
Compared with first quarter 2013, net sales increased 23% from $437,415 to $540,286, as a result of increased market penetration, gross profit moved up from $229,027 to $269,788, and net income swung from a loss of $17,272 to a profit of $71,205. Financials will be provided at www.kelyniam.com. "This is the strongest first quarter in the company's history", stated Tennyson Anthony, President and CEO. "Our progress is encouraging and it suggests there is a lot more room for the company to grow. Furthermore, we are working to increase our gross margins throughout 2014."
In addition, the company is excited to announce that the board has appointed Dr. Mark Smith, a prominent Nuerosurgeon, and Dr. Naveh Levy, a practicing Diagnostic Radiologist, to the board of directors.
Mark V Smith, M.D. is a neurosurgeon with over 20 years of clinical experience. He has also worked as a biomedical engineer. He graduated magna cum laude with a bachelor's degree in Electrical Engineering from the University of Maryland in 1980. After working two years as a biomedical engineer, he was admitted to medical school where he earned a doctorate of medicine at the University of Maryland in 1986. He completed his neurosurgery training at SUNY Upstate University Hospital in Syracuse, New York in 1993. He is also fellowship trained in pituitary surgery and epilepsy surgery. Dr. Smith was as an assistant professor of neurological surgery at SUNY Health Sciences Center in Syracuse, New York from 1994 to 1999 specializing in epilepsy and skull base surgery. In 1999 he started a private practice neurosurgery group in Utica, New York. Dr. Smith has received numerous awards and grants and is published in the fields of neuroanatomy, neurophysiology and neurosurgery.
Naveh Levy, M.D. completed his residency at the Cleveland Clinic in 2008 and an MRI Fellowship in 2009 at Michigan State University. He holds a medical degree from George Washington University School of Medicine in Washington, D.C.
"Kelyniam is in the business of taking raw data, a patient's CT scan, and creating a superior product with intricate details for the surgeon to implant in the patient. These new board members bring the technological acumen to complement both aspects of the business," stated Mr Anthony. "We are excited to have them join us."
=============================================================
Kelyniam Global Inc. Revenues Grow 54% from Prior Year
GlobeNewswire - Apr 07 08:30 EDT
Alert hits:/kl
Company Symbols: OTC-PINK:KLYG
Canton, CT, April 7, 2014 (GLOBE NEWSWIRE) -- Kelyniam Global Inc.(OTC: KLYG), a manufacturer of custom cranial implants, announces preliminary revenue of $1,857,516 for 2013. This represents an increase of 54% vs. sales of $1,206,227 in 2012. The Kelyniam product fit and quick turnaround has captured the attention of surgeons throughout the United States. The revenue increase reflects the continued rollout in many additional hospitals. The company will provide financials on their website, kelyniam.com, when they become available in final form from the Accounting Firm.
President and CEO Tennyson S. Anthony stated: "Although we are showing consistent growth and have become a profitable company in a relatively short time, rest assured we are focused on building a company that has the ability to grow at a much greater rate in the near future. My team and I have been working tirelessly to create a company that has the technology, economic fortitude, and operational efficiency to be the market leader in customized implants. We are just starting to see the fruits of our efforts."
=============================================================
Kelyniam Global Inc. Unveils New Product
Canton, CT, April 2, 2014 (GLOBE NEWSWIRE) -- Kelyniam Global Inc. has introduced a new product to the marketplace, the "IFS" (Integrated Fixation System) product. The product is patent pending and provides faster implantation, reduced hardware, cost savings and elimination of mundane tasks during the surgical procedure.
The design team at Kelyniam created this product with the surgeons needs in mind together with the realization of economic sensitivities by the hospitals. They carefully collected feedback and input from a multitude of surgeons and designed the product to make their surgeries more efficient.
Kelyniam will be unveiling the new product at the 82nd Annual AANS (American Association of Neurological Surgeons) meeting April 5-9, 2014 in San Francisco.
The company also expects to report financials for 2013 in the coming weeks.
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
===================================================================
KLYG.. $0.1388.. I think it's a table pounder but I need to see one more Qtr.. It's been my lottery ticket for 2 years.. Kelyniam Global Inc. turns profitable during the second quarter of 2013
Canton, CT, Sept. 25, 2013 (GLOBE NEWSWIRE) -- Kelyniam Global Inc. (OTC: KLYG) ("the company") is pleased to announce that it has posted its first ever quarterly profit, for the quarter ending June 30, 2013. Net income for the second quarter was $6,608. Sales in the second quarter were $593,355, up 35% from $438,415 in the first quarter 2013. Year to date sales were $1,031,770, up 253% from the same period in 2012.
The company continues to deploy capital towards marketing and organic growth, and to build market share as its customized PEEK implants are sold in more hospitals than ever. It has recently negotiated better terms for the DECD note secured last year, with the term of the note changing from 5 years to 10 without any increase in the interest rate.
Kelyniam will be an active participant in the Connecticut Economic Trade Mission to Australia later this week, traveling to both Sydney and Canberra, Australia. President & CEO Tennyson Anthony exclaimed, "While we are pleased with our second quarter performance, it is our goal to be used in all 50 states and internationally as well." He continued, "In fact, our growth is not only focused on geography, but on building on our existing products. The company will be announcing a new product in the months to come, one that we feel will turn heads."
The company will be posting the financial tables on the website www.kelyniam.com
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
Please visit our website at www.kelyniam.com for more information.
==========================================
KLYG.. $0.1078.. My LOTTERY TICKET,, It moves on air.. Now meeting projections made last year...
Kelyniam Global Inc. Announces Continued Revenue Growth & Approval to Sell Overseas
Canton, CT, May 30, 2013 (GLOBE NEWSWIRE) -- Kelyniam Global Inc. (OTC: KLYG), a growing company that designs, manufactures, and sells custom cranial/craniofacial implants, announced today its financial results for the year ending December 31, 2012 and also for the first quarter ended March 31, 2013.
Revenues for the year ending December 31, 2012 totaled $1.2 million. 2012 was the first full calendar year the company had manufactured and sold custom cranial implants in the United States. Revenues for the fourth quarter of 2012 were $414,982 up from $382,177 in the third quarter 2012.
First quarter 2013 revenues were a record $437,415, an increase of 207% from $210,635 in the first quarter of 2012. The increase in sales was attributed to continued marketing and promotional efforts across the United States. The first quarter 2013 marks the first time the company has broken even on an accrual basis.
The 2013 year brings the headwind of the medical device tax to the industry. Beginning Jan 2013 and unless Obamacare is repealed; Kelyniam will be liable for a 2.3% tax on all medical device sales.
A further note: Kelyniam is pleased to announce it has recently been approved to sell its custom cranial/craniofacial implants in Kuwait. It anticipates sales to begin in the coming months.
Related unaudited financial tables will be posted on the company's website www.kelyniam.com.
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
Please visit our website at www.kelyniam.com for more information.
Source: Kelyniam Global Inc.
2013 GlobeNewswire, Inc.
---------------------------------------------------
Kelyniam Custom Cranial Implants Receive Endorsement From Skull Based Neurosurgeon Dr. Ammirati of The Ohio State University Wexner Medical Center
Canton, CT, Jan. 29, 2013 (GLOBE NEWSWIRE) -- (OTC: KLYG) Kelyniam Custom Cranial Implants, designed to fill the boney void in a patient's skull, have been endorsed by Mario Ammirati, MD, Director of Skull Based Surgery, Stereotactic Radiosurgery and the Dardinger Microneurosurgical Skull Based Laboratory, Wexner Medical Center, at the Ohio State University. This is the first product Dr. Ammirati has ever endorsed.
Dr. Ammirati stated: "As a neurosurgeon specializing in skull based surgery and brain tumors, I am encouraged with the advancements Kelyniam has made in patient customized cranial implants. I am extremely happy with the precision fit and the fast service I receive with every case. Complex cranial defects resulting from trauma or oncologic resection present reconstructive challenges. No matter how complex the defect, Kelyniam's implant design team is very responsive to my needs. They understand the surgical plans and are quick to respond to my design requirements. The end result is a product that fits very well and is quick to implant, thereby reducing O.R. time and providing the patient with excellent aesthetic results."
----------------------------------------
Kelyniam Global Inc. Announces Record Revenues
GlobeNewswire - Jan 15 08:15 EDT
Alert hits:/kl
Company Symbols: OTC-PINK:KLYG
Canton, CT, Jan. 15, 2013 (GLOBE NEWSWIRE) --
Third Quarter
Kelyniam is pleased to announce record quarterly revenues of $382,177 for the third quarter ending September 30th 2012. This represents almost double the product revenue produced in the second quarter 2012. The company continues to penetrate the custom cranial implant marketplace and has sold implants to medical institutions in more than 20 different states. Furthermore, the company has sold the first maxiofacial implants in the fourth quarter as a result of the recent FDA 510k approval in late third quarter.
Fourth Quarter
The debut of Kelyniam maxiofacial implants in the fourth quarter was met with orders. These orders combined with existing custom cranial implant orders propelled revenues to approximately $400,000 for the fourth quarter, exceeding internal expectations of a slow quarter due to multiple holidays and fewer surgeries. Final fourth quarter numbers will be released once a full accounting is complete.
"The final two quarters of the year demonstrate that both the custom cranial and maxiofacial implant markets have capacity for a product of superior design. Management has worked hard to right the ship in 2012 and looks to build on the momentum in 2013" stated President and CEO Tennyson Anthony. "Kelyniam not only has created a product that fills the patient's cranial void, but is filling the void in the marketplace for a timely-delivered well-fitting product."
Upcoming Conference
Kelyniam will be exhibiting once again at the North American Skull Base Society (NASBS) February 15th - 17th, in Miami, FL.
Financial tables can be found on the company's website www.kelyniam.com
About Kelyniam Global, Incorporated
Kelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.
Please visit our website at www.kelyniam.com for more information.
ACGX.. $0.0056,, Push coming..?? looks like the Ask side is loaded and waiting for it to move some stock.. Converters,, bagged sellers or just flippers ,, time will tell but I'm in the converters camp.. Has any one checked the Transfer agent for the latest share count..??
It,, ( The latest share count ) was promised at one time to be updated weekly but there have been few updates in the past when conversions were taking place,, that is if history is any guide... hank
KLYG.. $0.19.. I sold a few this morning at $0.1388 because I was out at a Dr.'s Appointment but if I had not been there I would of been a buyer.. While this is/has been my lottery ticket I think it now has enough Qtr's under it's belt to qualify as a growth story in the making..
KLYG.. $0.19.. I sold a few this morning at $0.1388 because I was out at a Dr.'s Appointment but if I had not been there I would of been a buyer.. While this is/has been my lottery ticket I think it now has enough Qtr's under it's belt to qualify as a growth story in the making..
KLYG.. $0.19.. I sold a few this morning at $0.1388 because I was out at a Dr.'s Appointment but if I had not been there I would of been a buyer.. While this is/has been my lottery ticket I think it now has enough Qtr's under it's belt to qualify as a growth story in the making..
KLYG.. $0.19.. I sold a few this morning at $0.1388 because I was out at a Dr.'s Appointment but if I had not been there I would of been a buyer.. While this is/has been my lottery ticket I think it now has enough Qtr's under it's belt to qualify as a growth story in the making..
KLYG.. $0.19.. I sold a few this morning at $0.1388 because I was out at a Dr.'s Appointment but if I had not been there I would of been a buyer.. While this is/has been my lottery ticket I think it now has enough Qtr's under it's belt to qualify as a growth story in the making..
North Dakota exposure,, Mountainview Energy Ltd. Announces 2014 First Quarter Financial Results
Mountainview Energy Ltd. (QX) (USOTC:MNVWF)
CUT BANK, MT, May 30, 2014 /PRNewswire/ - Mountainview Energy Ltd. ("Mountainview" or the "Company") (TSXV: MVW) is pleased to announce its operating and financial results for the three months ended March 31, 2014.
Certain selected quarterly financial and operational information is outlined below and should be read in conjunction with Mountainview's reviewed unaudited interim consolidated financial statements and management's discussion and analysis ("MD&A") for the three months ended March 31, 2014 and the audited financial statements for the years ended December 31, 2013 and 2012 and the accompanying management discussion and analysis, which have been filed with the Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com) and also on the Company's website: www.mountainviewenergy.com.
Highlights
During the first quarter of 2014, Mountainview continued to build its production base by completing the two wells drilled at year end, 2013, which resulted in an increase in revenue.
Highlights of Mountainview's successful Q1 2014 are as follows:
• Completed a capital program of $7.9 million, completing 2 gross (1.9 net) wells at a 100% success rate.
• Average Q1 production of 898 boe/d, an increase of 230% over the average of 390 boe/d for Q1 2013.
• Exited Q1 with 1,284 boe/d of production with oil weighting of 87%, compared to 510 boe/d with 79% oil weighting for the prior period quarter.
• Funds flow from operations increased by 619% over the prior period quarter, with $.3 million for the quarter ended March 31, 2014, as compared to ($0.2) for the quarter ended March 31, 2013.
• Generated operating netbacks of $33.87 per boe in Q1 2014, an increase of 40% when compared to $24.12 per boe in Q1 2013.
($000's except per share amounts) Q1 2014 Q4 2013 Q3 2013 Q2 2013 Q1 2013 Q4 2012 Q3 2012 Q2 2012
Average production (boe/d) 898 1,183 711 703 391 194 190 157
Petroleum and natural gas sales 6,108 7,418 5,993 5,107 2,009 778 933 739
Operating netback (per boe) 33.87 34.39 26.13 24.98 24.12 (0.66) 26.93 22.25
Funds flow from operations 310 2,085 2,156 2,419 (207) 150 (177) (72)
Per share basic 0.00 0.02 0.02 0.03 nil nil nil nil
Per share diluted 0.01 0.02 0.02 0.02 nil nil nil nil
Net income (loss) (1,561) (3,141) (387) (1,065) (1,381) (7,344) (428) (362)
Per share basic (0.02) (0.00) (0.01) (0.02) (0.02) (0.08) (0.00) (0.01)
Per share diluted (0.02) (0.00) (0.01) (0.02) (0.02) (0.08) (0.00) (0.01)
Capital expenditures 7,910 16,584 7,262 1,682 21,401 6,489 1,137 2,814
Total assets
90,214 84,744 74,265 67,253 65,131 49,056 49,360 47,945
Net debt excluding financial derivatives 65,314 59,244 46,883 35,772 33,287 19,804 18,605 15,619
(1) Operating netback is a non-GAAP measure calculated as the average per boe of the Company's oil and gas sales plus realized gains on derivatives, less royalties, operating and transportation expenses.
(2) Funds flow from operations should not be considered an alternative to, or more meaningful than, cash flow from operating activities as determined in accordance with International Financial Reporting Standards as an indicator of Mountainview's performance. Funds flow from operations represents cash flow from operating activities prior to changes in non-cash working capital, transaction costs and decommissioning provision expenditures incurred. Mountainview also presents funds flow from operations per share whereby per share amounts are calculated using weighted average shares outstanding consistent with the calculation of earnings per share.
(3) Due to the anti-dilutive effect of Mountainview's net loss for the three months ended March 31, 2014 and 2013, the diluted number of shares is equal to the basic number of shares. Therefore, diluted per share amounts of the net loss are equivalent to basic per share amounts.
(4) Capital expenditures are a non-GAAP measure, calculated as the purchase or sale price of an asset, plus development capital expenditures added to PP&E. Corporate acquisitions are excluded from this measure.
(5) Net debt is a non-GAAP measure representing the total of bank indebtedness, accounts payables and accrued liabilities, less accounts receivables, deposits and prepaid expenses.
Corporate
As highlighted by the Company's quarter-end financial and operational results, Mountainview exited the quarter with increased production, offsetting natural declines from initial production from wells drilled in the fourth quarter of 2013. These declines resulted in lower average production on a quarter over quarter basis which produced a 18% decrease in oil and natural gas sales, while also showing a decrease in funds flow from operations and per boe netbacks when compared to the fourth quarter of 2013. The addition of production in late Q1 2014 is the result of Mountainview's continued focus and successful implementation of its capital plan in Divide County, ND. Operationally, the Company continues to improve on its completion technique and downhole assembly which is expected to increase initial production rates and recoverable reserves while lowering operating expenses. The results of the Q1 2014 capital plan further de-risked the southern extent of the 12 Gage asset, adding an additional infill drilling inventory with capital efficiencies associated with pad drilling.
Mountainview expects to continue its strategic shift to drilling higher working interest wells in 2014.
Financial
At quarter-end, Company net debt was $65.3 million and the Company had $46.1 million drawn on its available credit facility of $51.2 million. Funds flow from operations for Q1 2014 increased significantly from Q1 2013, reaching $0.3 million.
In response to exposure to volatility of differentials from WTI and industry concerns with respect to transportation restrictions in the Williston Basin, which translated into realized prices ranging from $69.40 per barrel of oil in Q1 2013, to $85.28 per barrel of oil in Q1, 2014, the Company has entered into a financial hedging program commencing in January, 2014. Mountainview had 50% of its production hedged for Q1, 2014, with a floor of $85.00 and a ceiling of $97.70. The Company plans to actively manage its hedging program as its production base grows.
Operations
The Company's Q1 2014 capital plan, including all drilling operations, was focused on its core 12 Gage asset in Divide County, N.D. The $7.9 million capital program in the quarter included the completion of 2 wells (1.9 net), with a 100% success rate. At year end 2013, these 2 wells (1.9 net) that had been drilled and were awaiting completion. The Company has selectively increased its working interest in its assets whenever appropriate as it has become more experienced operationally. This experience has resulted in decreased capital costs on a per well basis from $8.3 million per well to $6.3 million per well.
Outlook
Mountainview has continued to deliver on its strategy of production and reserve growth. With anticipated 2014 funds flow from operations in excess of $8 million, and available credit on its existing credit facility, Mountainview will continue to focus on the development of its core 12 Gage asset in Divide County, N.D.
The Company will continue to pursue an aggressive growth strategy using a combination of cash flow and available credit. Recent positive movement in both oil pricing and the WTI oil differentials, combined with the Company's new hedge position, allows Mountainview to remain confident in the long term sustainability of the 2014 capital plan.
With the de-risking of the 12 Gage drilling inventory, Mountainview has identified 72 infill Three Forks/Torquay locations. Adding Bakken potential, management believes that there are an additional 80 drilling locations, all on the 12 Gage acreage. With 152 potential drilling locations on the 12 Gage acreage, Mountainview is strongly positioned to organically grow production and reserves while being able to review acquisition opportunities to further diversify and enhance the Company's commodity and play type risk.
About Mountainview
Mountainview Energy Ltd. is a public oil and gas company listed on the TSX Venture Exchange, with a primary focus on the exploration, production and development of the Bakken and Three Forks Shale in the Williston Basin and the South Alberta Bakken.
Forward-Looking Statements
Certain information contained in this press release constitutes forward-looking statements. Statements relating to "reserves" are deemed to be forward-looking statements as they involve the implied assessment, based on certain estimates and assumptions, that the reserves described exist in the quantities predicted or estimated and can be profitably produced in the future. By their nature, forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond the Company's control including the impact of general economic conditions, industry conditions, volatility of commodity prices, currency fluctuations, environmental risks, competition from other industry participants, the lack of availability of qualified service providers, personnel or management, stock market volatility and ability to access sufficient capital from internal and external sources, inability to meet or continue to meet listing requirements, the inability to obtain required consents, permits or approvals and the risk that actual results will vary from the results forecasted and such variations may be material. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company's actual results, performance or achievement could differ materially from those expressed in or implied by, these forward-looking statements and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits the Company will derive therefrom.
The forward-looking statements contained in this press release are made as of the date of this press release. Mountainview disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Additionally, Mountainview undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.
Barrels of Oil Equivalent
The term barrels of oil equivalent ("boe") may be misleading, particularly if used in isolation. A boe conversion ratio of six thousand cubic feet of natural gas to one barrel of oil equivalent (6 mcf/bbl) is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. Given that the value ratio based on the current price of crude oil as compared to natural gas is significantly different from the energy equivalency of 6:1, utilizing a conversion on a 6:1 basis may be misleading as an indication of value. All boe conversions in this report are derived from converting gas to oil in the ratio of six thousand cubic feet of gas to one barrel of oil.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Mountainview Energy Ltd.
Copyright 2014 PR Newswire
North Dakota exposure,, Mountainview Energy Ltd. Announces 2014 First Quarter Financial Results
Mountainview Energy Ltd. (QX) (USOTC:MNVWF)
CUT BANK, MT, May 30, 2014 /PRNewswire/ - Mountainview Energy Ltd. ("Mountainview" or the "Company") (TSXV: MVW) is pleased to announce its operating and financial results for the three months ended March 31, 2014.
Certain selected quarterly financial and operational information is outlined below and should be read in conjunction with Mountainview's reviewed unaudited interim consolidated financial statements and management's discussion and analysis ("MD&A") for the three months ended March 31, 2014 and the audited financial statements for the years ended December 31, 2013 and 2012 and the accompanying management discussion and analysis, which have been filed with the Canadian securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com) and also on the Company's website: www.mountainviewenergy.com.
Highlights
During the first quarter of 2014, Mountainview continued to build its production base by completing the two wells drilled at year end, 2013, which resulted in an increase in revenue.
Highlights of Mountainview's successful Q1 2014 are as follows:
• Completed a capital program of $7.9 million, completing 2 gross (1.9 net) wells at a 100% success rate.
• Average Q1 production of 898 boe/d, an increase of 230% over the average of 390 boe/d for Q1 2013.
• Exited Q1 with 1,284 boe/d of production with oil weighting of 87%, compared to 510 boe/d with 79% oil weighting for the prior period quarter.
• Funds flow from operations increased by 619% over the prior period quarter, with $.3 million for the quarter ended March 31, 2014, as compared to ($0.2) for the quarter ended March 31, 2013.
• Generated operating netbacks of $33.87 per boe in Q1 2014, an increase of 40% when compared to $24.12 per boe in Q1 2013.
($000's except per share amounts) Q1 2014 Q4 2013 Q3 2013 Q2 2013 Q1 2013 Q4 2012 Q3 2012 Q2 2012
Average production (boe/d) 898 1,183 711 703 391 194 190 157
Petroleum and natural gas sales 6,108 7,418 5,993 5,107 2,009 778 933 739
Operating netback (per boe) 33.87 34.39 26.13 24.98 24.12 (0.66) 26.93 22.25
Funds flow from operations 310 2,085 2,156 2,419 (207) 150 (177) (72)
Per share basic 0.00 0.02 0.02 0.03 nil nil nil nil
Per share diluted 0.01 0.02 0.02 0.02 nil nil nil nil
Net income (loss) (1,561) (3,141) (387) (1,065) (1,381) (7,344) (428) (362)
Per share basic (0.02) (0.00) (0.01) (0.02) (0.02) (0.08) (0.00) (0.01)
Per share diluted (0.02) (0.00) (0.01) (0.02) (0.02) (0.08) (0.00) (0.01)
Capital expenditures 7,910 16,584 7,262 1,682 21,401 6,489 1,137 2,814
Total assets
90,214 84,744 74,265 67,253 65,131 49,056 49,360 47,945
Net debt excluding financial derivatives 65,314 59,244 46,883 35,772 33,287 19,804 18,605 15,619
(1) Operating netback is a non-GAAP measure calculated as the average per boe of the Company's oil and gas sales plus realized gains on derivatives, less royalties, operating and transportation expenses.
(2) Funds flow from operations should not be considered an alternative to, or more meaningful than, cash flow from operating activities as determined in accordance with International Financial Reporting Standards as an indicator of Mountainview's performance. Funds flow from operations represents cash flow from operating activities prior to changes in non-cash working capital, transaction costs and decommissioning provision expenditures incurred. Mountainview also presents funds flow from operations per share whereby per share amounts are calculated using weighted average shares outstanding consistent with the calculation of earnings per share.
(3) Due to the anti-dilutive effect of Mountainview's net loss for the three months ended March 31, 2014 and 2013, the diluted number of shares is equal to the basic number of shares. Therefore, diluted per share amounts of the net loss are equivalent to basic per share amounts.
(4) Capital expenditures are a non-GAAP measure, calculated as the purchase or sale price of an asset, plus development capital expenditures added to PP&E. Corporate acquisitions are excluded from this measure.
(5) Net debt is a non-GAAP measure representing the total of bank indebtedness, accounts payables and accrued liabilities, less accounts receivables, deposits and prepaid expenses.
Corporate
As highlighted by the Company's quarter-end financial and operational results, Mountainview exited the quarter with increased production, offsetting natural declines from initial production from wells drilled in the fourth quarter of 2013. These declines resulted in lower average production on a quarter over quarter basis which produced a 18% decrease in oil and natural gas sales, while also showing a decrease in funds flow from operations and per boe netbacks when compared to the fourth quarter of 2013. The addition of production in late Q1 2014 is the result of Mountainview's continued focus and successful implementation of its capital plan in Divide County, ND. Operationally, the Company continues to improve on its completion technique and downhole assembly which is expected to increase initial production rates and recoverable reserves while lowering operating expenses. The results of the Q1 2014 capital plan further de-risked the southern extent of the 12 Gage asset, adding an additional infill drilling inventory with capital efficiencies associated with pad drilling.
Mountainview expects to continue its strategic shift to drilling higher working interest wells in 2014.
Financial
At quarter-end, Company net debt was $65.3 million and the Company had $46.1 million drawn on its available credit facility of $51.2 million. Funds flow from operations for Q1 2014 increased significantly from Q1 2013, reaching $0.3 million.
In response to exposure to volatility of differentials from WTI and industry concerns with respect to transportation restrictions in the Williston Basin, which translated into realized prices ranging from $69.40 per barrel of oil in Q1 2013, to $85.28 per barrel of oil in Q1, 2014, the Company has entered into a financial hedging program commencing in January, 2014. Mountainview had 50% of its production hedged for Q1, 2014, with a floor of $85.00 and a ceiling of $97.70. The Company plans to actively manage its hedging program as its production base grows.
Operations
The Company's Q1 2014 capital plan, including all drilling operations, was focused on its core 12 Gage asset in Divide County, N.D. The $7.9 million capital program in the quarter included the completion of 2 wells (1.9 net), with a 100% success rate. At year end 2013, these 2 wells (1.9 net) that had been drilled and were awaiting completion. The Company has selectively increased its working interest in its assets whenever appropriate as it has become more experienced operationally. This experience has resulted in decreased capital costs on a per well basis from $8.3 million per well to $6.3 million per well.
Outlook
Mountainview has continued to deliver on its strategy of production and reserve growth. With anticipated 2014 funds flow from operations in excess of $8 million, and available credit on its existing credit facility, Mountainview will continue to focus on the development of its core 12 Gage asset in Divide County, N.D.
The Company will continue to pursue an aggressive growth strategy using a combination of cash flow and available credit. Recent positive movement in both oil pricing and the WTI oil differentials, combined with the Company's new hedge position, allows Mountainview to remain confident in the long term sustainability of the 2014 capital plan.
With the de-risking of the 12 Gage drilling inventory, Mountainview has identified 72 infill Three Forks/Torquay locations. Adding Bakken potential, management believes that there are an additional 80 drilling locations, all on the 12 Gage acreage. With 152 potential drilling locations on the 12 Gage acreage, Mountainview is strongly positioned to organically grow production and reserves while being able to review acquisition opportunities to further diversify and enhance the Company's commodity and play type risk.
About Mountainview
Mountainview Energy Ltd. is a public oil and gas company listed on the TSX Venture Exchange, with a primary focus on the exploration, production and development of the Bakken and Three Forks Shale in the Williston Basin and the South Alberta Bakken.
Forward-Looking Statements
Certain information contained in this press release constitutes forward-looking statements. Statements relating to "reserves" are deemed to be forward-looking statements as they involve the implied assessment, based on certain estimates and assumptions, that the reserves described exist in the quantities predicted or estimated and can be profitably produced in the future. By their nature, forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond the Company's control including the impact of general economic conditions, industry conditions, volatility of commodity prices, currency fluctuations, environmental risks, competition from other industry participants, the lack of availability of qualified service providers, personnel or management, stock market volatility and ability to access sufficient capital from internal and external sources, inability to meet or continue to meet listing requirements, the inability to obtain required consents, permits or approvals and the risk that actual results will vary from the results forecasted and such variations may be material. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company's actual results, performance or achievement could differ materially from those expressed in or implied by, these forward-looking statements and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or if any of them do so, what benefits the Company will derive therefrom.
The forward-looking statements contained in this press release are made as of the date of this press release. Mountainview disclaims any intention and assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Additionally, Mountainview undertakes no obligation to comment on the expectations of, or statements made by, third parties in respect of the matters discussed above.
Barrels of Oil Equivalent
The term barrels of oil equivalent ("boe") may be misleading, particularly if used in isolation. A boe conversion ratio of six thousand cubic feet of natural gas to one barrel of oil equivalent (6 mcf/bbl) is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. Given that the value ratio based on the current price of crude oil as compared to natural gas is significantly different from the energy equivalency of 6:1, utilizing a conversion on a 6:1 basis may be misleading as an indication of value. All boe conversions in this report are derived from converting gas to oil in the ratio of six thousand cubic feet of gas to one barrel of oil.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Mountainview Energy Ltd.
Copyright 2014 PR Newswire
Not a bad explanation of fracking..
http://mountainviewenergy.com/drilling/